<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304588</url>
  </required_header>
  <id_info>
    <org_study_id>CHIN-PLAGH-ST-001</org_study_id>
    <nct_id>NCT02304588</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot</brief_title>
  <official_title>Vascular Occlusive Diseases Such as Diabetic Foot Treated With Mesenchymal Stem Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mesenchymal stem cells with multidirectional differentiation potential,autologous stem cell
      transplantation into ischemic foot, make its differentiation to form new blood capillary,
      improve and restore the local blood flow.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>Frequency and severity of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Wound Area Regression of 40% or More at 6 Week</measure>
    <time_frame>6 week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Reduced pain</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Reduced pain, measured by VAS scale and use of analgesics</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Lower Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size &amp; patient weight).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>10-20 x 10^6 cells/20mL</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the age of 30-78 years old, men and women there is no limit.

          -  in accordance with the ministry of health in higher medical colleges and universities
             teaching material the sixth edition of the annals of diabetic foot diagnostic
             criteria.

          -  with severe lower limb ischemia (defined as the resting state of ankle brachial index
             (ABI) 0.4-0.85, accompanied by resting or intermittent toe line.

          -  treatment on a voluntary basis, and sign the informed consent.

        Exclusion Criteria:

          -  with severe heart, liver, kidney, lung function failure or general condition is very
             poor can't tolerate the stem cell transplant.

          -  clear over the past five years tumor markers in patients with malignant disease and
             blood levels increased significantly.

          -  the prodrome of acute infectious diseases.

          -  participated in clinical subjects within three months before test.

          -  adherence is poor, can not complete the course.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaobing FU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaobing FU</last_name>
    <phone>+86(10)937516</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>haojie Hao</last_name>
      <phone>+86(10)937516</phone>
    </contact>
    <contact_backup>
      <last_name>haojie Hao</last_name>
      <phone>+86(10)937516</phone>
      <email>haojieh@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xiaobing Fu</investigator_full_name>
    <investigator_title>Academician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

